OrthoEvidence, 3228 South Service Rd, Burlington, ON, Canada.
McMaster University, 1280 Main St W, Hamilton, ON, Canada.
Knee Surg Sports Traumatol Arthrosc. 2019 Jun;27(6):1974-1983. doi: 10.1007/s00167-018-5071-7. Epub 2018 Jul 25.
Intra-articular injections of corticosteroid (CS) and hyaluronic acid (HA) have individually demonstrated efficacy for knee osteoarthritis (OA); however, both treatments are limited by the trajectory of symptom relief. The combination of CS and HA in the management of knee OA may provide improved symptomatic relief for patients who are candidates for intra-articular therapies.
Electronic databases Medline, EMBASE and Cochrane Library were used to identify relevant publications. Randomized controlled trials (RCT) that evaluated intra-articular injections of combined CS and HA in comparison to HA alone were included. Outcomes eligible for meta-analysis were WOMAC pain, WOMAC total, OMERACT-OARSI responder rate, and treatment-related adverse events. Standardized mean differences (SMD) were calculated for continuous outcomes using an inverse variance method and a random-effects model. Odds ratios (OR) were calculated for dichotomous outcomes using the Mantel-Haenszel method and a random-effects model. Heterogeneity was assessed using the I statistic.
Eight trials (n = 751 patients) were included. Reduction in WOMAC pain scores at 2-4 weeks favoured the combined CS and HA group compared to HA alone [SMD 0.60, 95% CI (0.23, 0.97); p = 0.002, I = 75%]. Longer term improvements at 24-26 and 52 weeks WOMAC pain scores also favoured the combined CS and HA group {[SMD 0.25, 95% CI (0.09, 0.41); p = 0.002, I = 0%] and [SMD 0.39, 95% CI (0.01, 0.77); p = 0.05, I = 0%]} compared to HA alone, respectively. There were no significant differences in WOMAC total scores, OMERACT-OARSI responder rate, or treatment-related adverse events.
Combined intra-articular injections of CS and HA led to reductions in pain at 2-4, 24-26 and 52 weeks compared to HA injections alone.
Level II-meta-analysis.
关节内注射皮质类固醇(CS)和透明质酸(HA)均已证明对膝骨关节炎(OA)有效;然而,这两种治疗方法都受到症状缓解轨迹的限制。在 OA 的管理中联合 CS 和 HA 的治疗可能为适合关节内治疗的患者提供更好的症状缓解。
使用电子数据库 Medline、EMBASE 和 Cochrane Library 来确定相关出版物。纳入了评估 CS 和 HA 联合关节内注射与单独使用 HA 相比的随机对照试验(RCT)。有资格进行荟萃分析的结果是 WOMAC 疼痛、WOMAC 总分、OMERACT-OARSI 应答率和治疗相关不良事件。使用倒数方差法和随机效应模型计算连续结果的标准化均数差(SMD)。使用 Mantel-Haenszel 方法和随机效应模型计算二分类结果的优势比(OR)。使用 I 统计量评估异质性。
纳入了八项试验(n=751 名患者)。与单独使用 HA 相比,在 2-4 周时,联合 CS 和 HA 组 WOMAC 疼痛评分的降低更具优势[SMD 0.60,95%置信区间(0.23,0.97);p=0.002,I=75%]。在 24-26 周和 52 周时,联合 CS 和 HA 组 WOMAC 疼痛评分的长期改善也具有优势[SMD 0.25,95%置信区间(0.09,0.41);p=0.002,I=0%]和[SMD 0.39,95%置信区间(0.01,0.77);p=0.05,I=0%]与单独使用 HA 相比。在 WOMAC 总分、OMERACT-OARSI 应答率或治疗相关不良事件方面,两组之间没有显著差异。
与单独使用 HA 相比,联合 CS 和 HA 关节内注射可降低 2-4、24-26 和 52 周时的疼痛。
II 级-荟萃分析。